| Print
DBV TECHNOLOGIES (DBV)
DBV TECHNOLOGIESThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Address
177-181 avenue Pierre Brossolette
Montrouge
FRA
92120
Telephone
+3 301 55427878
Forecast key dates
| Name | Key Date |
|---|---|
| DBV Technologies SA Third Quarter Earnings Results for 2026 | 2026-10-28T00:00:00 |
| DBV Technologies SA Second Quarter Earnings Results for 2026 | 2026-07-29T00:00:00 |
| DBV Technologies SA Annual General Meeting for 2026 | 2026-06-11T14:00:00 |
| DBV Technologies SA First Quarter Earnings Results for 2026 | 2026-04-30T00:00:00 |
| DBV Technologies SA Annual Report for 2025 | 2026-04-10T00:00:00 |
| DBV Technologies SA Fourth Quarter Earnings Conference Call for 2025 | 2026-03-24T00:00:00 |
| DBV Technologies SA Fourth Quarter Earnings Results for 2025 | 2026-03-24T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| VITESSE Topline Results Conference Call | 2025-12-16T17:00:00 |
| Guggenheim 2(nd) Annual Healthcare Innovation Conference | 2025-11-11T14:00:00 |
| DBV Technologies SA Third Quarter Earnings Results for 2025 | 2025-10-28T00:00:00 |
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-09T11:30:00 |
| DBV Technologies SA Second Quarter Earnings Results for 2025 | 2025-07-29T00:00:00 |
| DBV Technologies SA Annual General Meeting for 2025 | 2025-06-11T14:00:00 |
| Citizens JMP Life Sciences Conference | 2025-05-07T11:00:00 |
| DBV Technologies SA First Quarter Earnings Results for 2025 | 2025-04-30T00:00:00 |
| DBV Technologies SA Annual Report for 2024 | 2025-04-11T00:00:00 |
| DBV Technologies SA Fourth Quarter Earnings Conference Call for 2024 | 2025-03-24T00:00:00 |
| DBV Technologies SA Fourth Quarter Earnings Result for 2024 | 2025-03-24T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.